BioMedWire Editorial Coverage: The ability to accurately detect drug and alcohol intoxication has long been a persistent challenge across industries, from law enforcement and workplace safety to healthcare and public health management. Traditional methods such as breathalyzers, blood tests and urine screenings are often limited by their invasiveness, delayed results or inability to assess real-time impairment, particularly in cases involving multiple substances. As patterns of substance use evolve and the societal costs of impaired behavior continue to rise, the demand for faster, more scalable and noninvasive diagnostic solutions is becoming increasingly urgent. MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) ( Profile ) is advancing a novel approach that leverages artificial intelligence (“AI”) and voice analysis to predict intoxication from short speech samples. By focusing on the human voice as a measurable indicator of internal physiological and cognitive states, the company is working to develop a platform capable of detecting impairment across a range of substances in real-time. This approach not only addresses a critical gap in existing detection methods but also reflects a broader shift toward AI-driven, noninvasive diagnostics with the potential to transform regulatory enforcement, workplace safety and public health outcomes. MindBio joins other key companies operating at the forefront of health, AI and diagnostics technologies, including HeartFlow Inc. (NASDAQ: HTFL), Recursion Pharmaceuticals Inc. (NASDAQ: RXRX), Tempus AI Inc. (NASDAQ: TEM) and…
AUSTIN, Texas, May 11, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: The ability to accurately detect drug and alcohol intoxication has long been a persistent challenge across industries, from law enforcement and workplace safety to healthcare and public health management. Traditional methods such as breathalyzers, blood tests and urine screenings are often limited by their invasiveness, delayed results or inability to assess real-time impairment, particularly in cases involving multiple substances. As patterns of substance use evolve and the societal costs of impaired behavior continue to rise, the demand for faster, more scalable and noninvasive diagnostic solutions is becoming increasingly urgent. MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) (profile) is advancing a novel approach that leverages artificial intelligence (AI) and voice analysis to predict intoxication from short speech samples. By focusing on the human voice as a measurable indicator of internal physiological and cognitive states, the company is working to develop a platform capable of detecting impairment across a range of substances in real-time. This approach not only addresses a critical gap in existing detection methods but also reflects a broader shift toward AI-driven, noninvasive diagnostics with the potential to transform regulatory enforcement, workplace safety and public health outcomes. MindBio joins other key companies operating at the forefront of health, AI and diagnostics technologies, including HeartFlow Inc. (NASDAQ: HTFL), Recursion Pharmaceuticals Inc. (NASDAQ: RXRX), Tempus AI Inc. (NASDAQ: TEM) and Butterfly Network Inc. (NYSE: BFLY).
SAN FRANCISCO, April 23, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today announced it will release financial results for the first quarter of 2026 after market close on Thursday, May 14, 2026. Management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET on May 14, 2026.
MOUNTAIN VIEW, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today reported financial results for the fourth quarter and full year ended December 31, 2025.
MOUNTAIN VIEW, Calif., March 16, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today announced new clinical evidence and a landmark registry launch that together advance the company's vision of transforming CAD management across every stage of the patient journey. At the American College of Cardiology (ACC) Annual Scientific Session, Heartflow is presenting new clinical evidence that further establishes AI-powered Heartflow Plaque Analysis as the leading tool for identifying high-risk patients earlier and guiding more effective medical management.
MOUNTAIN VIEW, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today announced that members of management will participate in a fireside chat at the upcoming Morgan Stanley Technology, Media & Telecom Conference. The presentation will take place in San Francisco, CA, on Tuesday, March 3, 2026, at 10:45 a.m. PT / 1:45 p.m. ET.
MOUNTAIN VIEW, Calif., Feb. 13, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today announced it will release financial results for the fourth quarter and full year of 2025 after market close on Wednesday, March 18, 2026. Management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET on March 18, 2026.
MOUNTAIN VIEW, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in artificial intelligence (AI) technology for coronary artery disease (CAD), today announced that members of management will present at the upcoming 44th Annual J.P. Morgan Healthcare Conference. The presentation will take place on Tuesday, January 13, 2026, at 1:30 p.m. PT / 4:30 p.m. ET.
Lesion-specific FFRCT predicts individual cardiovascular outcomes and delivers greater-than-modeled cost savings for real-world population in FISH&CHIPS analyses from England’s National Health Service
A billionaire family office has made a big bet on a newly public AI-driven heart diagnostics company—here’s what long-term investors should take from the move.
